Koji × Odin

英灵殿的短期目标是打造最强AI制药平台，核心差异在于同时建模和设计小分子、蛋白、RNA与DNA的全模态分子世界模型。2026年的关键变化不是技术拐点，而是资本市场活跃后获得了数千万美元融资，团队达到三十人；LD模型、任意模态组合设计及平台不做管线的选择，构成后续验证与商业化的主要观察点。

泓君 × 周叶斌 × 张璐

美国医疗AI已从“要不要整合”转向“一定要整合”，最现实的切入口是medical coding、billing与prior authorization等高成本、强规则流程。HIPAA、数据控制和无幻觉部署构成准入壁垒，OpenAI与微软争夺医院工作流的同时，OpenEvidence的高估值、广告模式和低迁移成本仍留下商业化风险。

Daphne Zohar × Bruce Booth × Eric Schmidt

Biotech’s year-end pause looks like healthy stock-picker consolidation, with XBI near 124 while mediocre data from Pyxis and Nektar were heavily punished.Nearly $9B of October-November follow-ons is creating indigestion, as first-day performance increasingly sets discounts for subsequent deals.Confidential S-1 flips could fuel a Q1 IPO rush, but recycled issuers and a disrupted FDA policy backdrop make quality and execution the key risks.

Sarah Guo × Elad Gil

AI leaders are emerging in foundation models, coding, medical scribing, and customer success, while sales productivity, financial-analyst tooling, accounting, and pharma remain open.The winning application playbook combines vertical workflows, proprietary data, distribution, and user-generated knowledge, while startup mergers may strengthen defense against incumbents; neglected fertility, longevity, and world-model opportunities remain constrained by financing, regulation, and uncertain commercialization.

Sarah Guo × Noubar Afeyan

Noubar Afeyan’s Flagship Pioneering model treats parallel startup creation as a repeatable institution for underwriting uncertainty, using variation, selection and iteration rather than forecasting breakthroughs.Generate Biomedicines has more than 15 computationally designed antibody programs, but Phase III trials, FDA regulation, pricing power and platform funding remain decisive constraints, as Joule’s technically successful but economically unviable outcome demonstrates.